InflaRx to Present at Upcoming Virtual Investor Events
August 06 2020 - 7:30AM
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical
company developing anti-inflammatory therapeutics by targeting the
complement system, will present at several upcoming virtual
investor events in August and September as follows:
BTIG Virtual Biotechnology
Conference: August 10th – 11th
A BTIG analyst will host a fireside chat with
Prof. Niels C. Riedemann, Chief Executive Officer and Founder of
InflaRx, to discuss the Company’s pipeline and upcoming catalysts
on Monday, August 10th at 12:30pm EST. The Company
will also hold virtual 1X1 meetings.
A live webcast of the fireside chat will be
provided on the InflaRx website in the Investors section under
Events & Presentations. A replay will be available following
the live event.
H.C. Wainwright Annual Global Investment
Conference: September 14th – 16th
The Company will give a presentation and conduct
virtual 1X1 meetings.
A live webcast of the Company’s presentation
will be provided on the InflaRx website in the Investors section
under Events & Presentations.
Oppenheimer Fall Healthcare Life
Sciences & MedTech Summit: September 21st – 23rd
The Company will give a presentation and conduct
virtual 1X1 meetings.
About IFX-1:
IFX-1 is a first-in-class monoclonal anti-human
complement factor C5a antibody, which highly and effectively blocks
the biological activity of C5a and demonstrates high selectivity
towards its target in human blood. Thus, IFX-1 leaves the formation
of the membrane attack complex (C5b-9) intact as an important
defense mechanism, which is not the case for molecules blocking the
cleavage of C5. IFX-1 has been demonstrated to control the
inflammatory response driven tissue and organ damage by
specifically blocking C5a as a key “amplifier” of this response in
pre-clinical studies. IFX-1 is believed to be the first monoclonal
anti-C5a antibody introduced into clinical development.
Approximately 300 people have been treated with IFX-1 in clinical
trials, and the antibody has been shown to be well tolerated. IFX-1
is currently being developed for various indications, including
Hidradenitis Suppurativa, ANCA-associated vasculitis, Pyoderma
Gangraenosum and COVID-19 pneumonia.
About InflaRx N.V.:
InflaRx (Nasdaq: IFRX) is a clinical-stage
biopharmaceutical company focused on applying its proprietary
anti-C5a technology to discover and develop first-in-class, potent
and specific inhibitors of C5a. Complement C5a is a powerful
inflammatory mediator involved in the progression of a wide variety
of autoimmune and other inflammatory diseases. InflaRx was founded
in 2007, and the group has offices and subsidiaries in Jena and
Munich, Germany, as well as Ann Arbor, MI, USA. For further
information please visit www.inflarx.com.
Contacts:InflaRx
N.V.Jordan Zwick – Global Head of Business Development
& Corporate StrategyEmail: jordan.zwick[at]inflarx.deTel: +1
917-338-6523MC Services AGKatja Arnold, Laurie
Doyle, Andreas Jungfer Email: inflarx[at]mc-services.eu Europe: +49
89-210 2280US: +1-339-832-0752
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “believe,” “estimate,”
“predict,” “potential” or “continue” and similar expressions.
Forward-looking statements appear in a number of places throughout
this release and may include statements regarding our intentions,
beliefs, projections, outlook, analyses and current expectations
concerning, among other things, our ongoing and planned preclinical
development and clinical trials; the impact of the COVID-19
pandemic on the Company; the timing of and our ability to
commence and conduct clinical trials; potential results from
current or potential future collaborations; our ability to make
regulatory filings, obtain positive guidance from regulators, and
obtain and maintain regulatory approvals for our product
candidates; our intellectual property position; our ability to
develop commercial functions; expectations regarding clinical trial
data; our results of operations, cash needs, financial condition,
liquidity, prospects, future transactions, growth and strategies;
the industry in which we operate; the trends that may affect the
industry or us and the risks, uncertainties and other factors
described under the heading “Risk Factors” in InflaRx’s periodic
filings with the Securities and Exchange Commission. These
statements speak only as of the date of this press release and
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Given these risks, uncertainties and
other factors, you should not place undue reliance on these
forward-looking statements, and we assume no obligation to update
these forward-looking statements, even if new information becomes
available in the future, except as required by law.
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024